Related Experiment Video
Updated: May 9, 2025
High efficiency, Site-specific Transfection of Adherent Cells with siRNA Using Microelectrode Arrays MEA
Published on: September 13, 2012
Effective targeting of E2F1 transcription factor via siRNA gene electrotransfer in HT-29 colorectal carcinoma
Tanja Jesenko1, Simona Kranjc Brezar1, Ziva Pisljar2
1Institute of Oncology Ljubljana, Zaloska cesta 2, Ljubljana 1000, Slovenia; Faculty of Medicine, University of Ljubljana, Vrazov trg 2, Ljubljana 1000, Slovenia.
Abstract:
Colorectal cancer (CRC) remains a significant global health concern, with survival outcomes heavily dependent on the stage at diagnosis. Targeted therapies offer a promising approach to improve patient outcomes, particularly by addressing molecular drivers of tumor progression. One such target is the E2F1 transcription factor, a key regulator of the cell cycle and a contributor to proliferation, differentiation, apoptosis, metastasis, and chemoresistance in CRC. Previous studies have demonstrated the efficacy of E2F1 silencing via siRNA-loaded nanoliposomes in reducing tumor cell growth, but challenges such as immunogenicity and off-target effects have limited their in vivo application. In this study, we evaluated the potential of gene electrotransfer (GET) as a non-viral delivery system for delivery of therapeutic siRNA targeting E2F1 in the HT-29 CRC model. In vitro experiments showed effective silencing of E2F1 expression and a significant reduction in HT-29 cell survival. Subsequent in vivo studies confirmed the therapeutic potential of siE2F1 GET, with results demonstrating tumor growth delay, decreased proliferation, and increased necrosis in the tumors. This study establishes proof-of-principle for targeting E2F1 in CRC using GET, showcasing its versatility and therapeutic potential.
Insights
Gene electrotransfer (GET) effectively silenced E2F1 in colorectal cancer (CRC) cells, reducing tumor growth and increasing necrosis. This non-viral delivery method shows promise for targeted CRC therapy.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Colorectal cancer (CRC) poses a significant global health challenge, with survival rates linked to diagnostic stage.
- Targeted therapies offer improved outcomes by addressing molecular drivers of CRC progression.
- E2F1 transcription factor is crucial for cell cycle regulation and implicated in CRC proliferation, metastasis, and chemoresistance.
Purpose of the Study:
- To evaluate gene electrotransfer (GET) as a non-viral delivery system for siRNA targeting E2F1 in colorectal cancer.
- To assess the efficacy of E2F1 silencing using GET in vitro and in vivo.
Main Methods:
- Utilized the HT-29 colorectal cancer cell line for in vitro and in vivo studies.
- Employed gene electrotransfer (GET) for the delivery of small interfering RNA (siRNA) targeting E2F1.
- Assessed E2F1 expression, cell survival, tumor growth, proliferation, and necrosis.
Main Results:
- In vitro experiments demonstrated effective E2F1 silencing and reduced HT-29 cell survival.
- In vivo studies showed significant tumor growth delay, decreased proliferation, and increased necrosis in tumors treated with siE2F1 GET.
- GET proved to be a viable non-viral delivery method for therapeutic siRNA in a CRC model.
Conclusions:
- Gene electrotransfer (GET) is a promising non-viral delivery strategy for targeting E2F1 in colorectal cancer.
- siE2F1 delivered via GET exhibits therapeutic potential, inhibiting tumor progression and enhancing treatment effects.
- This study provides proof-of-principle for GET as a versatile tool in CRC gene therapy.
